Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium
JCO Oncology Practice · 2026-11 · 22 (11) · 1976-1985
DOI: 10.1200/op-25-00450 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JCO Oncology Practice, 2026-11. Verfasst von Allen S Ho und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Human Papillomavirus Viruses, Circulating Tumor DNA, Papillomavirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Circulating tumor DNA (ctDNA) assays have evolved into transformative tools capable of disrupting current management paradigms, including that of human papillomavirus (HPV)–positive oropharyngeal carcinoma (OPC). Despite readily available assays, guidance on its implementation remains undefined. METHODS A systematic literature review, an expert physician panel, and patient interviews were used to develop consensus items on circulating tumor HPV DNA (ctHPVDNA) use. A hybrid Delphi approach was applied with California Head and Neck Consortium (CHNC) experts to appraise consensus over iterative rounds of feedback. Voting continued until thematic saturation was achieved. RESULTS In total, 33 CHNC experts participated, representing various entities (academic medical center, integrated managed care system, county hospital, Veterans Affairs hospital, community cancer center, private practice). Item development led to 32 statements across five domains, which later expanded to 33 items. Thematic saturation was reached after three rounds, with complete participation (33 of 33 votes) achieved in each round. Of these statements, 63.6% (21 of 33) reached strong consensus, 9.1% (3 of 33) reached consensus, 12.1% (4 of 33) was found to have no consensus, and 15.1% (5 of 33) was rejected. Key statements highlighted the strong consensus that ctHPVDNA was a valuable tool appropriate for diagnosis and surveillance settings, but not for screening or treatment modifications in current clinical practice. Despite the promise of this technology, there was strong consensus that randomized clinical trials should be performed to optimize its use in HPV+ OPC in the setting of potential increased costs. CONCLUSION Using currently available evidence and expertise, we establish a pragmatic framework of consensus recommendations for ctHPVDNA use. Such statements of varying strength will help bridge gaps in knowledge and lead to judicious implementation of assays into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
- The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
- Division of Medical Oncology, Department of Medicine, University of California Irvine (UCI), Irvine, CA.
- Department of Otolaryngology-Head and Neck Surgery, University of California Davis (UCD), Davis, CA.
- Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA.
- US Department of Veterans Affairs, Veterans Health Administration, Washington, DC.
ORCID-Profile: Allen S Ho, Justin T Moyers, Michelle M Chen, Charles S Coffey, Theresa Guo, Jeremy P Harris, F Christopher Holsinger, Niels Kokot, Daniel Kwon, Andrew Larson, Jon Mallen-St Clair, Abie Mendelsohn, Sagus Sampath, Liyang Tang, Jacob Thomas, Deborah J Wong, Zachary S Zumsteg
Zitieren
APA
Ho, A. S., Moyers, J. T., Attarian, S., Banker, R., Birkeland, A., Chen, M. M., Coffey, C. S., Guo, T., Haidar, Y., Harris, J. P., Holsinger, F. C., Inman, J., Jang, J. K., Kokot, N., Kwon, D., Larson, A., Lin, A., Maghami, E., Mallen-St Clair, J., …, & Zumsteg, Z. S. (2026). Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium. JCO Oncology Practice, 22(11), 1976-1985. https://doi.org/10.1200/op-25-00450
Vancouver
Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, et al. Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium. JCO Oncology Practice. 2026;22(11):1976-1985. doi:10.1200/op-25-00450
BibTeX
@article{Ho2026,
author = {Ho, Allen S and Moyers, Justin T and Attarian, Shirin and Banker, Rupali and Birkeland, Andrew and Chen, Michelle M and Coffey, Charles S and Guo, Theresa and Haidar, Yarah and Harris, Jeremy P and Holsinger, F Christopher and Inman, Jared and Jang, Julie K and Kokot, Niels and Kwon, Daniel and Larson, Andrew and Lin, Alice and Maghami, Ellie and Mallen-St Clair, Jon and Mendelsohn, Abie and Mita, Alain C and Ryan, William R and St John, Maie and Sampath, Sagus and Scher, Kevin S and Sinha, Uttam and Tang, Liyang and Thomas, Jacob and Tjoa, Tjoson and Wai, Katherine C and Walgama, Evan S and Wong, Deborah J and Zumsteg, Zachary S},
title = {Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium},
journal = {JCO Oncology Practice},
year = {2026},
volume = {22},
number = {11},
pages = {1976--1985},
doi = {10.1200/op-25-00450}
}
EUVIMED